A General Review of the antibiotics Mupirocin and Cefuroxime on Paronychia caused by S. Aureus and S. Pyogenes species

Authors

  • Jiayi Yang

DOI:

https://doi.org/10.61173/jrc3at62

Keywords:

Paronychia, skin infections, cephalosporins, mupirocin, antibiotic resistance

Abstract

This article will focus on the treatment of paronychia with cefuroxime and mupirocin, which are two different types of antibiotics frequently prescribed by medical professionals for the treatment of nail infections caused by common pathogenic bacterial species. Cefuroxime is an antibiotic isolated from a fungus and is characterized as a type of class II cephalosporin that belongs to the class of B-lactam antibiotics that binds to penicillin-binding-proteins in bacteria, therefore inhibiting bacterial peptidoglycan (cell wall) synthesis and kills the cell. Mupirocin (more commonly known as Bactroban) is another antibiotic that is isolated from a fellow bacteria species and works by obstructing bacterial aminoacyl-tRNA synthesis in various species of bacteria that may be susceptible to the mechanism. However, the application of these antibiotics onto infected regions does not guarantee a complete elimination of the pathogens due to the rise of antibiotic resistance genes throughout the bacterial population. A short discussion will follow all the presented materials, as well as the referenced materials.

References

[1] Leggit JC. Acute and Chronic Paronychia. Am Fam Physician. 2017 Jul 1;96(1):44-51. PMID: 28671378.

[2] Cleveland Clinic. “Paronychia (Nail Infection): What Is It, Symptoms, Causes, and Treatment.” Cleveland Clinic, 1 Nov. 2022, clevelandclinic.org/health/diseases/22223-paronychianail-infection. Accessed 15 Aug. 2024.

[3] DermNet. “Paronychia (Nail Fold Infection): Causes, Images, Treatment, and More.” DermNet, 2023, dermnetnz.org/ topics/paronychia-nail-fold-infection. Accessed 15 Aug. 2024

[4] “Impetigo.” *Mayo Clinic*, Mayo Foundation for Medical Education and Research, 27 Apr. 2023, https://www.mayoclinic. org/diseases-conditions/impetigo/symptoms-causes/syc- 20352352. Accessed 10 Aug. 2024.

[5] Relhan, Vineet et al. “Management of chronic paronychia.” Indian journal of dermatology vol. 59,1 (2014): 15-20. doi:10.4103/0019-5154.123482

[6] Natsis NE, Cohen PR. Coagulase-Negative Staphylococcus Skin and Soft Tissue Infections. Am J Clin Dermatol. 2018 Oct;19(5):671-677. doi: 10.1007/s40257-018-0362-9. PMID: 29882122.

[7] “Nail: Structure, Function, Growth.” Encyclopædia Britannica, Encyclopædia Britannica, Inc., 3 Apr. 2023, britannica.com/science/nail-anatomy. Accessed 15 Aug. 2024.

[8] “Nail Anatomy: Parts, Names, Diagrams.” Human Body Parts Anatomy, 24 Jan. 2022, https://humanbodypartsanatomy. com/nail-anatomy-parts-names-diagrams/. Accessed 10 Aug. 2024.

[9] InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. In brief: Structure of the nails. [Updated 2021 Dec 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513133/

[10] Sizar O, Leslie SW, Unakal CG. Gram-Positive Bacteria. [Updated 2023 May 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470553/

[11] Wakim, Maria, and Paramedics Grewal. “Innate Immune System.” Human Biology, LibreTexts, 22 May 2023, https://bio. libretexts.org/Bookshelves/Human_Biology/Human_Biology_ (Wakim_and_Grewal)/20%3A_Immune_System/20.4%3A_ Innate_Immune_System. Accessed 10 Aug. 2024.

[12] Catania, Louis J.. “The adaptive (aka “acquired”) immune system: from friend to foe.” The Paradox of the Immune System (2022): 25–43. doi:10.1016/B978-0-323-95187-6.00006-6.

[13] https://bio.libretexts.org/Bookshelves/Human_Biology/ Human_Biology_(Wakim_and_Grewal)/20%3A_Immune_ System/20.4%3A_Innate_Immune_System. Accessed 10 Aug. 2024.

[14] Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. Chapter 9, The Humoral Immune Response. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK10752/

[16] Pollitt, Eric J G, and Stephen P Diggle. “Defining motility in the Staphylococci.” Cellular and molecular life sciences : CMLS vol. 74,16 (2017): 2943-2958. doi:10.1007/s00018-017- 2507-z

[17] Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002 Sep;8(9):881-90. doi: 10.3201/eid0809.020063. PMID: 12194761; PMCID: PMC2732559.

[18] Kaplan JB, Mlynek KD, Hettiarachchi H, Alamneh YA, Biggemann L, Zurawski DV, Black CC, Bane CE, Kim RK, Granick MS. Extracellular polymeric substance (EPS)- degrading enzymes reduce staphylococcal surface attachment and biocide resistance on pig skin in vivo. PLoS One. 2018 Oct 10;13(10):e0205526. doi: 10.1371/journal.pone.0205526. PMID: 30304066; PMCID: PMC6179274.

[19] van Wamel WJ, Rooijakkers SH, Ruyken M, van Kessel KP, van Strijp JA. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Dean&Francis Jiayi Yang Staphylococcus aureus are located on beta-hemolysin-converting bacteriophages. J Bacteriol. 2006 Feb;188(4):1310-5. doi: 10.1128/JB.188.4.1310-1315.2006. PMID: 16452413; PMCID: PMC1367213.

[20] Nourbakhsh F, Namvar AE. Detection of genes involved in biofilm formation in Staphylococcus aureus isolates. GMS Hyg Infect Control. 2016 Mar 22;11:Doc07. doi: 10.3205/ dgkh000267. PMID: 27303652; PMCID: PMC4804124.

[21] Idrees, Muhammad et al. “Staphylococcus aureus Biofilm: Morphology, Genetics, Pathogenesis and Treatment Strategies.” International Journal of Environmental Research and Public Health vol. 18,14 7602. 16 Jul. 2021, doi:10.3390/ijerph1814760

[22] Krzyściak, W et al. “The pathogenicity of the Streptococcus genus.” European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology vol. 32,11 (2013): 1361-76. doi:10.1007/ s10096-013-1914-9

[23] Young PG, Proft T, Harris PW, Brimble MA, Baker EN. Structure and activity of Streptococcus pyogenes SipA: a signal peptidase-like protein essential for pilus polymerisation. PLoS One. 2014 Jun 9;9(6):e99135. doi: 10.1371/journal. pone.0099135. PMID: 24911348; PMCID: PMC4049620.

[24] “Streptococcus pyogenes.” MicrobeWiki, Kenyon College, https://microbewiki.kenyon.edu/index.php/Streptococcus_ pyogenes#Pathology. Accessed 10 Aug. 2024.

[25] “Blood Agar: Composition, Preparation, Uses, and Types of Hemolysis.” Microbe Online, https://microbeonline.com/bloodagar-composition-preparation-uses-and-types-of-hemolysis/. Accessed 10 Aug. 2024.

[26] Eric Sauvage, Frédéric Kerff, Mohammed Terrak, Juan A. Ayala, Paulette Charlier, The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis, FEMS Microbiology Reviews, Volume 32, Issue 2, March 2008, Pages 234–258, https://doi.org/10.1111/j.1574-6976.2008.00105.x

[27] Navratna, Vikas et al. “Molecular basis for the role of Staphylococcus aureus penicillin binding protein 4 in antimicrobial resistance.” Journal of bacteriology vol. 192,1 (2010): 134-44. doi:10.1128/JB.00822-09

[28] Pancu, Daniel Florin et al. “Antibiotics: Conventional Therapy and Natural Compounds with Antibacterial Activity-A Pharmaco-Toxicological Screening.” Antibiotics (Basel, Switzerland) vol. 10,4 401. 7 Apr. 2021, doi:10.3390/ antibiotics10040401

[29] “Cephalosporins/Beta-Lactamase Inhibitors.” Drugs. com, 24 Mar. 2022, https://www.drugs.com/drug-class/ cephalosporins-beta-lactamase-inhibitors.html. Accessed 10 Aug. 2024.

[31] “Cefuroxime.” DrugBank, https://go.drugbank.com/drugs/ DB01112. Accessed 10 Aug. 2024.

[32] “Cefuroxime.” MedicineNet, https://www.medicinenet.com/ cefuroxime/article.htm. Accessed 10 Aug. 2024.

[33] Lim D, Strynadka NC. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol. 2002 Nov;9(11):870-6. doi: 10.1038/ nsb858. PMID: 12389036.

[34] Fishovitz, Jennifer et al. “Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus.” IUBMB life vol. 66,8 (2014): 572-7. doi:10.1002/iub.1289

[35] Rubio Gomez, Miguel Angel, and Michael Ibba. “Aminoacyl-tRNA synthetases.” RNA (New York, N.Y.) vol. 26,8 (2020): 910-936. doi:10.1261/rna.071720.119

[36] Erwin DZ, Chen P. Mupirocin. [Updated 2024 Jan 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK599499/

[38] Yasmeen, Ayesha, et al. “Exploring Mechanisms of Mupirocin Resistance and the Role of Isoleucyl-tRNA Synthetase in Staphylococcus Aureus.” Biochemical Society Transactions, vol. 52, no. 3, 2024, pp. 1109-1116. Portland Press, https://portlandpress.com/biochemsoctrans/articleabstract/52/3/1109/234567/Exploring-mechanisms-ofmupirocin-resistance-and?redirectedFrom=fulltext. Accessed 10 Aug. 2024.

[39] Gurney, R., Thomas, C.M. Mupirocin: biosynthesis, special features and applications of an antibiotic from a Gram-negative bacterium. Appl Microbiol Biotechnol 90, 11–21 (2011). https:// doi.org/10.1007/s00253-011-3128-3

[40] “Mupirocin.” DrugBank, https://go.drugbank.com/drugs/ DB00410. Accessed 10 Aug. 2024.

[41] Capobianco, J O et al. “Mechanism of mupirocin transport into sensitive and resistant bacteria.” Antimicrobial agents and chemotherapy vol. 33,2 (1989): 156-63. doi:10.1128/ AAC.33.2.156

[42] Twilley D, Reva O, Meyer D, Lall N. Mupirocin Promotes Wound Healing by Stimulating Growth Factor Production and Proliferation of Human Keratinocytes. Front Pharmacol. 2022 Apr 11;13:862112. doi: 10.3389/fphar.2022.862112. PMID: 35479318; PMCID: PMC9035886.

Downloads

Published

2025-07-06